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Abstract 
 
Objectives: Oropharyngeal squamous cell carcinoma (OPSCC) is divided in two different disease 
entities depending on HPV involvement. We investigated differences in presenting symptoms and 
clinical findings in patients with HPV-positive and negative OPSCC tumors. 
 
Methods: Altogether 118 consecutive patients diagnosed with primary OPSCC between 2012 and 
2014 at the Helsinki University Hospital were included. HPV-status of the tumors was assessed by 
PCR detection of HPV DNA and immunostaining with p16-INK4a antibody. 
 
Results: Fifty-one (47.7 %) of the patients had HPV-positive and 56 (52.3 %) had HPV-negative 
tumors. Forty-nine (49/51, 96.1 %) of the HPV+ tumors were also p16+ showing high concordance. 
The most common presenting symptom among HPV+/p16+ patients was a neck mass (53.1 %) 
whereas any sort of pain in the head and neck area was more frequently related to the HPV-/p16- 
(60.0 %) group. HPV+/p16+ tumors had a tendency to locate in the tonsillar complex and more 
likely had already spread into regional lymph nodes compared with HPV-/p16- tumors. Smoking 
and alcohol consumption were significantly more common among HPV-/p16- patients but also 
rather common among HPV+/p16+ patients. 
 
Conclusion: The present analysis of symptoms and signs confirm that OPSCC can be dichotomized 
in two distinct disease entities as defined by HPV status.  
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Introduction 
Oropharyngeal squamous cell carcinoma (OPSCC) incidence has been rapidly increasing and HPV 
infection is considered to be the most significant causal factor responsible for this [1-6]. The 
majority of HPV-positive head and neck cancers are located in the oropharyngeal region [1,7]. HPV 
infection is an independent risk factor for OPSCC despite tobacco and alcohol use, and nowadays 
up to 70 % of newly diagnosed OPSCCs are HPV positive [1,2,6,7]. Nevertheless, heavy smoking 
and alcohol consumption are still major risk factors for OPSCC. 
 
Numerous studies have indicated that HPV-positive and HPV-negative OPSCC patients are divided 
into two different disease groups by different demographic factors, risk profiles and tumor 
characteristics [1,6,8-10]. Majority of patients affected by HPV-positive OPSCC are found to be 
younger, generally healthier, sexually active and belong to higher socio-economical group. On the 
contrary, the HPV-negative OPSCC patients are generally older, have heavy smoking history, and 
among them profuse alcohol consumption is more common compared with HPV-positive 
patients.[9,11] The HPV-positive tumors are found to be smaller by T stage, have well-defined 
borders, and although by the time of diagnosis have more likely spread into regional lymph nodes 
and nevertheless have more favorable prognosis when compared with HPV-negative tumors 
[1,9,10,13-15].  On the other hand, smoking and alcohol use strongly impair the prognosis even 
among HPV-positive patients [12].  
 
Analysis and awareness of the symptoms are important as oral and oropharyngeal cancer patients 
are generally diagnosed relatively late at an advanced stage, which impairs prognosis and survival 
[15,16]. Generally, OPSCCs do not induce symptoms until they are large enough (>2 cm or T2) 
[16] causing local pressure to nearby structures, and at this point they have often already spread into 
regional lymph nodes [10,17]. Diagnosis may be delayed also by patient-dependent factors [16,18]. 
Nevertheless, waiting time for diagnosis and treatment has decreased by time in head and neck 
cancers in general [19]. 
 
In an effort to potentially facilitate early diagnosis of OPSCC we wanted to characterize in detail 
the presenting symptoms and clinical findings of HPV-positive and -negative OPSCC among our 
patients.  
 
Materials and Methods 
 
Study population 
 
The present study is based on a cohort of 118 consecutive patients with newly diagnosed primary 
OPSCC treated at the Department of Otorhinolaryngology – Head and Neck Surgery at the Helsinki 
University Hospital during a 2-year time period between February 2012 and February 2014. The 
study was approved by the Research Ethics Board at the Helsinki University Hospital. 
 
The inclusion criterion was a newly diagnosed OPSCC with no previous primary cancer. Clinical 
data were collected from electronic medical records. Data included gender, age at diagnosis, 
comorbidities as defined by the Charlson Comorbidity Index, presenting symptoms, and the time 
between the start of the presenting symptoms and the time of OPSCC diagnosis. The type of 
presenting symptoms was categorized in four different types: 1) neck mass, 2) pain in the head and 
neck area, 3) dysphagia/globus, and 4) other (e.g. bleeding, weight loss and asymptomatic). 
 
History of tobacco smoking was defined as ‘never’, ‘former use’, or ‘present use’. The magnitude 
of cigarettes smoked was estimated as years of daily cigarette packages (20 cigarettes) consumed. 
Alcohol use was estimated as ‘none’, ‘moderate drinking’, and ‘heavy alcohol use’. Heavy alcohol 
use was estimated as drinking during the past few years more than 24 standard drinks (12g of 
ethanol) a week for men and more than 16 standard drinks a week for women. 
 
Tumor location was divided into four different categories: 1) tonsil, 2) base of tongue, 3) soft 
palate, or 4) posterior pharyngeal wall. Tumor spread and stage were evaluated using the TNM 
classification. Tumor grade was recorded to evaluate the histology.  
 
p16-INK4a immunohistochemistry 
 
We detected the p16-INK4a status by immunohistochemistry (IHC) on paraffin embedded formalin 
fixed tissue samples. Positive p16 expression was defined when over 70 % of tumor cells were 
positive.  Xylene was used for deparaffinization and rehydration was done in graded series of 
alcohol.  PreTreatment-module (Lab Vision Corp., UK Ltd, UK) was used to treat the tissue slides 
in Tris-HCl buffer (pH 8.5), and endogenous peroxidase was blocked with 0.3% Dako REAL 
Peroxidase-Blocking Solution. Monoclonal mouse anti-human p16-INK (9517 CINtec Histology 
Kit, MTM laboratories, Germany) was used as primary antibody. 
 
HPV PCR 
 
PCR assay was used for detection of HPV DNA in tissue samples. DNA was extracted from 4-10 
um diameter sections cut from paraffin embedded formalin fixed sections and amplified with primer 
sets 1 and 2 from the Multiplex HPV Genotyping Kit® (DiaMex GmbH, Germany). A negative 
control contained no genomic DNA to confirm the absence of a contamination in the amplification 
reactions. HPV genotyping was performed with a Multiplex HPV Genotyping Kit® (DiaMex 
GmbH, Germany) which detects 24 LR- and HR-HPV-genotypes. The labeled hybrids were 
analyzed with a Luminex LX-100 analyzer (Bio-Plex 200 System, Bio-Rad Laboratories, Hercules, 
USA). 
 
Statistical analysis 
 
Data were analyzed with a statistical software program (IBM SPSS Statistics 22, IBM, Somers, IL, 
USA). The results are presented as mean, range, or as the number of patients when appropriate. The 
independent samples t-test was used for parametric comparisons, whereas the Mann-Whitney U-test 
was used with non-parametric data. The Pearson chi-square test was used for frequency data. A 
two-sided p-value of less than 0.05 was considered statistically significant.  
 
Results 
 
Altogether, 118 consecutive newly diagnosed oropharyngeal cancer patients were evaluated. Of the 
patients 89 (75.4 %) were male and the mean age was 62 years (range, 41 - 84).  
 
Immunohistochemical p16 status was determined for all primary tumor samples except for one case 
where the staining could only be made from a lymph node metastasis. This lymph node metastasis 
was p16 positive and the primary tumor located in the pharyngeal wall. Of the primary tumor samples 
80 (67.8 %) were p16 positive and 38 (32.2 %) were p16 negative. 
 
PCR assay for detection of HPV DNA was done for all except for eleven missing samples (107/118).  
Fifty-one (51/107, 47.7 %) of the patients were HPV positive and 56 (56/107, 52.3 %) HPV negative.  
 
All the demographic and clinical parameters were divided into three different subgroups as follows: 1) 
HPV+/p16+, 2) HPV-/p16- and 3) HPV+/p16-. We compared the two first groups with each other. 
Furthermore, all p16-positive patients with a known HPV association were compared with p16-/HPV- 
patients (group 2). Clinical and tumor specific characteristics of p16-positive but HPV-negative 
patients were close to group 1 patients. Thus, the comparison of HPV-/p16+ group with other 
subgroups was not relevant. Two patients (2/107) were HPV positive but p16 negative and these are 
not included in the analyses and tables. 
 
Of the tumors HPV+/p16+ was found in 49 (46.7 %) of the 105 tumor samples and 36 (33.3 %) 
patients were HPV-/p16- whereas 21 (20.0 %) patients were p16 positive but HPV negative. The 
concordance of p16 status determining HPV DNA association was 96.1 % (49/51) and specificity was 
62.5 % (35/56). 
 
Smoking and former smoking classes were significantly more common among HPV-/p16- patients 
when compared with HPV+/p16+ and with all p16-positive patients. However, smoking was also 
rather common among HPV+/p16+ cases (63.3 %). We investigated the HPV-positive cases regarding 
to their smoking status (HPV+ smokers/ex-smokers vs. HPV+ never smokers) but this aspect had no 
statistically significant influence on the presenting symptoms or sings (data not shown). Alcohol use 
in general showed no significant difference between different groups but heavy alcohol use was 
significantly more common among HPV-/p16- patients when compared with HPV+/p16+ or to p16-
positive patients. Comorbidities determined by Charlson Comorbidity index showed no differences 
between different groups.  
The median time from onset of symptoms to diagnosis seemed to be slightly lower (2.8 months) 
among HPV+/p16+ patients compared with HPV-/p16- patients (3.0 months) although the 
difference was not significant. The clinical characteristics of the 105 OPSCC patients are shown in 
Table 1. 
 
Among HPV+/p16+ patients neck mass was the most common presenting symptom (26/49, 53.1 %) 
and it was statistically significantly (OR 3.82 CI 95% 1.45 – 10.05) more common compared with 
HPV-/p16-. Majority of the HPV-/p16- patients (21/35, 60.0 %) indicated any sort of pain in the head 
and neck area as a presenting symptom. Only seven patients had two presenting symptoms, which 
could not be separated temporarily. All the results of the presenting symptoms are shown in Table 2.  
 
The most common tumor location in every subgroup was tonsillar complex and among HPV+/p16+ 
patients it was significantly more common location (77.6 %, OR 4.61 CI 95% 1.79 – 11.89) 
compared with HPV-/p16- group. Among HPV-p16- patients the second most common location was 
soft palate (10/35, 28.6 %) where it located statistically significantly more often (p <0.001) than in 
HPV+/p16+ or p16-positive patients. Tumor locations are presented in Table 3. 
 
There was no significant statistical difference in T stage between different groups. Nodal metastases 
were more common among HPV+/p16+ patients when compared with HPV-/p16-. N2b was the 
most common (26/49, 53.1 %) N stage among HPV+/p16+ patients being significantly (OR 3.27 CI 
95% 1.27 – 8.39) more frequent when compared with HPV-/p16-. Distant metastases were present 
in four cases. The most usual clinical stage was IVa in every group but it was significantly (p = 
0.001) more common among HPV+/p16+ patients (37/49, 75.5 %) compared with HPV-p16-. In 
addition among HPV+/p16+ patients the histological tumor grade was significantly higher 
compared with HPV-p16- patients. Majority (43/49, 87.8%) of the HPV+/p16+ tumors were of 
grade III and most (17/34, 50.0 %) of the HPV-p16- tumors were of grade II. Regarding both these 
grades the difference was found to be significant between the groups. Tumor characteristics are 
shown in Table 4.  
Discussion 
 
We present a retrospective study on 118 consecutive patients with newly diagnosed oropharyngeal 
cancer. Our aim was to determine the presenting symptoms and clinical findings of HPV-positive 
and HPV-negative OPSCC patients in order to define characteristics of these two cancer groups and 
to aid better detection of OPSCC at an early stage. Our analysis included newly diagnosed OPSCC 
patients during a two-year follow-up in our referral area of 1.6 million inhabitants covering close to 
one-third of the entire Finnish population.  
 
HPV status was evaluated by both p16 IHC as well as by HPV PCR of paraffin embedded tissue 
slices. Immunohistochemical staining of p16 is a sensitive method to screen for HPV in OPSCC and 
HPV PCR is a rather specific test for HPV involvement. We defined HPV-positive cases as being 
positive for both p16 IHC and HPV PCR and HPV-negative cases as being negative for both the 
above assays. Forty-nine (49/51) of the HPV DNA positive patients were also p16 positive showing 
high concordance (96.1 %). However, 21 out of the 70 p16-positive cases were HPV-DNA negative. 
This may indicate that there may be some other mechanisms than HPV-induced mechanisms that lead 
to p16 up-regulation. On the other hand, during the course of carcinogenesis HPV DNA might be 
deleted once p16 gets permanently up-regulated. Of note was that the clinical and tumor 
characteristics of p16-positive but HPV-negative patients and also p16-positive and HPV-positive 
patients resembled each other suggesting that these tumors may share some aspects of oncogenesis. 
There were also two cases that were HPV positive but p16 negative. The reasons for this phenomenon 
remain unclear but possible explanations may include DNA contamination or the presence of HPV 
DNA that is unrelated to carcinogenesis. Another limitation of our approach was that although p16 
IHC was done for all cases (n = 118) HPV PCR could only be performed on 107 of the cases. Yet, the 
number of single positive cases was relatively small and the strength of our approach was that 
defining the HPV status by both the p16 IHC and HPV PCR is a rather reliable method to dissect 
between HPV-positive and -negative cases. 
Neck mass was the most common presenting symptom among HPV-positive patients whereas any 
sort of pain in the head and neck area was the most often present among HPV-negative patients. A 
clear majority of the latter patients had a rather nonspecific pain sensation described as sore throat 
and only a few patients had odynophagia, ear pain, or jaw pain. McIlwain et al. in 2014 [20] showed 
similar results but the limitation of their study was that the HPV status was only evaluated by p16 
IHC. Similarly as in previous studies [3,6,11] the tonsillar complex was the most common tumor 
location in our study within both groups although it was significantly more usual among HPV-
positive when compared with HPV-negative patients. Interestingly, among HPV-/p16- patients soft 
palate was the second most common tumor location and significantly more common compared with 
HPV+/p16+ patients. Prior reports [3,11,12,19,20] have shown that T class is usually lower and N 
class higher among HPV-positive patients compared with HPV-negative patients. In the present study 
T class was lower among HPV-positive patients but the difference compared with HPV negative was 
not statistically significant probably due to small amount of HPV-negative cases. In our material N 
class was significantly higher among HPV-positive patients compared with HPV-negative patients, 
which is in line with earlier reports. In both groups the most common clinical stage was IVa. In 
conclusion, our results verify the earlier findings [10,11,20] that HPV-positive tumors are smaller by 
T class and generally present with a neck mass when these have already spread to local lymph nodes 
whereas HPV-negative tumors are larger by T class and typically expand locally causing only local 
symptoms such as sore throat.   
 
A clear majority of the patients were male, which supports prior reports [2,3,6,10,11-13,17,20]. 
Some previous studies [3,9,11,13] have shown that HPV-positive patients are more likely to be 
younger compared with HPV-negative patients but we did not find any clear statistically significant 
age difference between these groups, which is in line with some other earlier reports [10,20]. 
Tobacco smoking and alcohol consumption were significantly more frequent among HPV-negative 
patients compared with HPV-positive patients as reported by earlier studies [3,11,12,17,20]. 
However, even two thirds of the HPV-positive patients were current smokers or ex-smokers in the 
present series which is line in with few other studies [3,12]. In addition, we found no significant 
difference in the Charlson Comorbidity Index results between these two groups. This points out an 
interesting observation that HPV-positive OPSCC patients are not always younger, healthier, non-
smokers, and moderate alcohol users as reported by some studies [9,11]. It may indicate that 
alcohol consumption and tobacco use are rather common among Finnish OPSCC patients regardless 
of their HPV status. Ang et al. in 2010 showed that OPSCC patients should be divided not just by 
their HPV status but as well according to tobacco use and especially according to their smoking 
pack years [12] as prolonged smoking may lead to numerous mutations and extensive tumor 
heterogeneity, which may make oncologic treatment challenging. We observed that the presenting 
symptoms of HPV-positive and -negative patients were on average somewhat different reflecting 
the difference in the pathogenesis of these tumors. Smoking was mainly associated with HPV-
negative tumors but additionally many HPV-positive patients were smokers or had a history of 
smoking. Thus we analyzed whether the smoking status of HPV-positive patients (no smoking 
history vs. current smoker or previous smoker) would be associated with the type of symptom 
presented. Our analysis revealed that smoking status within the HPV positive patient group did not 
statistically significantly stratify the patients according to their symptoms presented. This may 
indicate that the mutation leading to over-expression of p16 remains the major factor contributing to 
the oncogenesis of the tumors. We therefore suggest, that more than the signs and symptoms, HPV 
and p16 status are the relevant factors when determining the best therapeutic option and prognosis 
for this patient population. 
 
Conclusion 
The present analysis of symptoms and signs confirm that OPSCC can be dichotomized in two distinct 
disease entities as defined by HPV status. Tobacco use and alcohol use were rather common among 
both of our patient groups.  
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